Anticipated $-0.89 EPS for Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of June, 15

May 17, 2018 - By Jenna Rose

On June, 15 is awaited Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)’s earnings report, Faxor reports. Analysts forecast 48.85 % diference or $-0.89 from the $-1.74 EPS from 2017. After $-0.75 EPS report last quarter, Wall Street now sees 18.67 % negative EPS growth of Biohaven Pharmaceutical Holding Company Ltd.. BHVN touched $29.95 during the last trading session after $0.18 change.Biohaven Pharmaceutical Holding Company Ltd. has volume of 453,190 shares. Since May 17, 2017 BHVN has 0.00% and is . BHVN underperformed the S&P500 by 11.55%.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders.The company has $1.16 billion market cap. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia.Last it reported negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

For more Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news announced recently go to: Prnewswire.com, Seekingalpha.com, Streetinsider.com, Prnewswire.com or Globenewswire.com. The titles are as follows: “Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients …” announced on May 09, 2018, “Biohaven Pharma announces key milestones for 2018” on May 15, 2018, “Biohaven (BHVN) to Present Additional Phase 3 Rimegepant Data at AAN 2018 on April 22nd” with a publish date: April 19, 2018, “Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results” and the last “Factors of Influence in 2018, Key Indicators and Opportunity within BIOHAVEN PHARM, WEC Energy Group, Axon …” with publication date: April 19, 2018.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.